Maetzold Derek J's Form 4 filing
Castle Biosciences IncCSTL · filed Sep 15, 2026
- Accession no.
- 0001628280-26-062047
- Filed
- Sep 15, 2026, 4:08 PM ET
- Trade date
- Sep 11, 2026
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $464.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Common Stock | MOption exerciseAcquired | +8,584 | $2.39 | +$20,515.76 | 30,063 | Direct | |
| Sep 11, 2026 | Common Stock | SSaleDisposed | −8,361 | $32.00F2 | −$267,552 | 21,702 | Direct | |
| Sep 11, 2026 | Common Stock | SSaleDisposed | −3,124 | $32.00F2 | −$99,968 | 14,517 | Indirect | |
| Sep 11, 2026 | Common Stock | SSaleDisposed | −2,656 | $32.00F2 | −$84,992 | 12,339 | Indirect | |
| Sep 11, 2026 | Common Stock | SSaleDisposed | −223 | $32.78 | −$7,309.94 | 21,479 | Direct | |
| Sep 11, 2026 | Common Stock | SSaleDisposed | −83 | $32.78 | −$2,720.74 | 14,434 | Indirect | |
| Sep 11, 2026 | Common Stock | SSaleDisposed | −71 | $32.78 | −$2,327.38 | 12,268 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Common Stock | MOption exerciseDisposed | −8,584 | $0.00 | $0 | 16,745 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $31.700 to $32.508, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 3 transactions in Table I.